rhGH improves height in patients with PTPN11+ Noonan syndrome
Individuals with Noonan syndrome harbouring pathogenic variations in the PTPN11 gene respond well to treatment with recombinant human growth hormone, retrospective study data show.
Individuals with Noonan syndrome harbouring pathogenic variations in the PTPN11 gene respond well to treatment with recombinant human growth hormone, retrospective study data show.
Health-related quality of life in women with Turner syndrome bears little or no relation to their height and whether they received growth hormone treatment as a child, say researchers.
Data from clinical practice support the option of adding gonadotrophin-releasing hormone analogue to growth hormone therapy in some clinical situations to extend the treatment window and optimise final height in children with idiopathic short stature.
Research shows that growth hormone deficiency and central precocious puberty can occur in children several years after traumatic brain injury, even among those with normal pituitary function 1 year after the event.
A study of patients with mutations or terminal deletions in the insulin-like growth factor 1 receptor gene shows that the majority are small for gestational age, short and microcephalic, with an elevated serum IGF-1 level.
A girl aged 15 years and 2 months is referred to the Endocrine Clinic for short stature and delayed puberty.